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A B S T R A C T
Purpose
On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell
lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT)
followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD).
Patients and Methods
Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40
to 52.8 Gy and cisplatin 30 mg/m2 weekly). Three cycles of VIPD (etoposide 100 mg/m2 days 1
through 3, ifosfamide 1,200 mg/m2 days 1 through 3, cisplatin 33 mg/m2 days 1 through 3, and
dexamethasone 40 mg days 1 through 4) were scheduled after CCRT.
Results
All patients completed CCRT, which resulted in 100% response that included 22 complete
responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of
30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three
cycles of VIPD, whereas four patients did not because they withdrew (n  2) or because they had
an infection (n 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses;
95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively.
Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients
experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates
were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively.
Conclusion
Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.
J Clin Oncol 27:6027-6032. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Extranodal natural killer (NK)/T-cell lymphoma
(ENKTL) shows a poor response to anthracycline-
based chemotherapy, such as cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP)
or CHOP-like regimens,1-3 because of the fre-
quent expression of a multidrug-resistant P-
glycoprotein.4,5 The use of radiotherapy as initial
treatment was reported to produce a greater com-
plete response rate than chemotherapy.6-8 However,
when ENKTL is treated with radiation alone, local
and systemic failures are observed frequently, even
when the disease is in early stage, and especially
within 2 years of the completion of treatment.8-12
Therefore, a newer treatment strategy for stages IE to
IIE ENKTL is required to improve response rate and
survival. An association of radiation dose with re-
sponse and survival was suggested previously,12,13
but minimization of the radiation dose should be
considered because of the adverse effects and the risk
of secondary malignancy associated with the use of
radiotherapy. Thus, we designed a concurrent che-
moradiotherapy (CCRT) regimen with 40 Gy of ra-
diation and weekly administration of cisplatin as a
radiosensitizer. In addition, in consideration of the
risk of systemic relapse after CCRT, we added sys-
temic chemotherapy that consisted of ifosfamide
and methotrexate, which are not affected by
P-glycoprotein, and etoposide, which is known to be
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effective for Epstein-Barr virus (EBV) –associated lymphoprolifera-
tive disorders.14,15 We report here the results of our phase II, prospec-
tive study that consisted of CCRT followed by systemic chemotherapy.
PATIENTS AND METHODS
Eligibility Criteria
Thirty patients were enrolled from April 2006 to October 2007. To be
eligible for enrollment, patients were required to have a biopsy-proven diag-
nosis of nasal ENKTL, to be at least 18 years old, to have disease classified as
Ann Arbor stage IE or IIE, to have measurable disease, to have an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 to 2, and to
have a life expectancy greater than 12 weeks. Patients also had to have adequate
hematologic function (ie, hemoglobin  9.0 g/dL, absolute neutrophil
count  1,500/L, and platelets  100,000/L), renal function (ie, serum
creatinine  1.5 mg/dL, creatinine clearance  50 mL/min), and hepatic
function (ie, total bilirubin two times the upper limit of normal and AST
 three times upper limit of normal). Diagnosis of ENKTL was based on
the presence of histologic features and immunophenotypes compatible
with ENKTL (eg, cytoplasmic CD3, CD20–, CD56, positive for cytotoxic
molecules, positive for EBV by fluorescence in situ hybridization). The exclu-
sion criteria were prior or concomitant malignant tumors and any coexisting
medical problems of sufficient severity to prevent full compliance with the
study protocol. ENKTL with non-nasal sites, such as skin or gastrointestinal
tract, was excluded even if it was localized. Other subtypes of non-Hodgkin’s
lymphoma (NHL), including myeloid/NK cell precursor acute leukemia, blas-
tic NK cell lymphoma/precursor NK cell lymphoblastic leukemia, aggressive
NK cell leukemia, and peripheral T-cell lymphoma unspecified, were ex-
cluded. All patients provided written informed consent. This study was ap-
proved by the institute review board of each hospital.
Treatment and Dose Modifications
The treatment scheme is shown in Figure 1 and consisted of CCRT
followed by three cycles of etoposide, ifosfamide, cisplatin, and dexametha-
sone (VIPD). After immobilization of the patient, computed tomography
(CT) simulation was performed to determine the appropriate radiation ther-
apy doses for each patient. The radiation target volume covered the gross
clinical lesions plus adequate margins. All patients received three-dimensional
(3D) conformal radiation therapy by using 4 or 6 MV photons generated from
a linear accelerator. The addition of elective lymphatic irradiation was deter-
mined on an individual basis. The median total dose to the gross lesion was 40
Gy, and the daily dose was 2 Gy for most patients, though it was 1.8 Gy for four
patients. Three to five weeks after the completion of CCRT, VIPD chemother-
apy was given every 3 weeks for up to three cycles (Fig 1). Because VIPD is a
more-intensive regimen than CHOP or CHOP-like regimens, and because
severe hematologic toxicities were observed in our pilot study, we chose three
cycles of VIPD to avoid unnecessary toxicities. This treatment schema was
derived from a pilot study of nine patients in whom we observed 100%
objective response, including eight complete responses (CR) and one partial
response (PR), after CCRT. The CRs were maintained after VIPD chemother-
apy. However, all patients experienced febrile neutropenia, so we reduced the
dosage of ifosfamide from 1,500 mg/m2 to 1,200 mg/m2 (Fig 1). All drugs were
administered only if the absolute neutrophil count was greater than 1,500/L
and the platelet count was greater than 75,000/L before each cycle. If either
the neutrophils or platelets were lower than these levels, treatment was delayed
for 7 days. Granulocyte colony-stimulating factor was administered for occur-
rences of grades 3 to 4 neutropenia. Dosages of ifosfamide and etoposide were
reduced by 25% if absolute neutrophil counts and platelet counts recovered to
1,000 to 1,499/L and to  50,000/L, respectively, after a 1-week delay. If
neutropenia (ie, absolute neutrophil count 1,000/L) and thrombocytope-
nia (ie, platelets50,000/L) persisted for 2 weeks, the patient was withdrawn
from this study. If patients experienced grade 2 or higher nonhematologic
toxicities, treatment was interrupted until the toxicity resolved to grades 0 to 1.
If creatinine clearance was less than 40 mL/min before a cycle, VIPD treatment
was delayed for up to 2 weeks. VIPD was restarted after the creatinine clearance
recovered to more than 40 mL/min. If the creatinine clearance did not recover,
cisplatin was omitted from the next VIPD.
Evaluation
Baseline evaluation were performed 14 days or less before enrollment,
and all patients were staged according to the Cotswold modification of the Ann
Arbor staging system, which included history taking, physical examination,
complete blood count, serum biochemistry with lactate dehydrogenase
(LDH), bone marrow aspiration and trephine biopsy, endoscopic examina-
tion of the nasal and oral cavities by otorhinolaryngologists, CT scanning or
magnetic resonance imaging (MRI) of the involved lesions, CT scanning of
the chest and abdomen-pelvis, and positron emission tomography (PET).
Quantitative polymerase chain reaction (PCR) for EBV DNA in peripheral
blood also was performed to determine the EBV viral load. All of these
studies were performed before treatment and after completion of CCRT and
VIPD, and they were repeated every 3 to 6 months thereafter to monitor
disease progression.
Assessment
Treatment response was assessed according to WHO criteria.16 CR was
defined as disappearance of all previously measurable lesions and absence of
any new tumor lesions. PR was defined as a decrease of at least 50% in the
product of two perpendicular diameters of each measurable lesion. Stable
disease (SD) was defined as a decrease of less than 50% or an increase of less
than 25% in tumor size, and progressive disease (PD) was defined as greater
than 25% increase in the product of the two diameters of at least one tumor or
as the presence of a newly developed lesion. Every patient received a laryngo-
scopic exam before and after CCRT and after completions of VIPD to confirm
the pathologic CR. The primary end point was the response rate, which was
calculated as the proportion of patients classified as CR and PR. The secondary
end points were progression-free survival (PFS), overall survival (OS), and
toxicity. PFS was defined as the time from the date of enrollment to the date of
documented disease progression, and it was censored at the date of the last
Concurrent chemoradiotherapy
Weekly cisplatin 30 mg/m2 IV
3-5 weeks
VIPD every 3 weeks (3 cycles)
Radiation (1.8-2 Gy/5 daily fractions)
VIPD VIPD VIPD
D1-D3 etoposide 100 mg/m2 IV over 90 mins
D1-D3 ifosfamide 1,200 mg/m2 IV over 1 hr
D1-D3 mesna 240 mg/m2 IV over 15 mins
D1-D3 cisplatin 33 mg/m2 IV over 1 hr
D1-D4 dexamethasone 40 mg/d by mouth or IV
Fig 1. Treatment scheme. VIPD, etopo-
side, ifosfamide, cisplatin, and dexameth-
asone; IV, intravenous.
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follow-up visit. OS was measured from the date of enrollment to the date of
death as a result of any cause, and it was censored at the date of the last
follow-up visit. Toxicity was evaluated before each treatment cycle according
to the National Cancer Institute Common Terminology Criteria of Adverse
Events, version 3.0.
Statistical Analysis
CR rates for stages IE to IIE ENKTL after radiotherapy were reported
previously to be approximately 70%.17,18 Therefore, we calculated sample size
to be sufficient to reject a 70% CR rate in favor of a target CR rate of 90%,
according to Simon’s optimal two-stage design.19 If a target level of interest is
assumed as p1 0.90, and a lower activity level is assumed as p0 0.70, six
patients needed to be accrued; if four or more CRs were observed, the trial
would be continued. Planned accrual was for 27 patients; if CR was observed in
22 or more patients, the treatment would continue into a phase III trial. This
design provided a probability of .05 of accepting a treatment worse than p0
and a probability of .20 for rejecting a treatment better than p1. If we assume
that the dropout rate is 10%, the total accrual needed to be 30 patients. The
Kaplan-Meier method was used to calculate PFS and OS, and survival curves
were compared by the log-rank test. A two-sided P value of less than .05 was
considered significant.
RESULTS
Characteristics of Patients
The characteristics of the patients are summarized in Table 1. The
median age was 48.5 years (range, 23 to 73 years); 86.7% of all patients
were younger than 60 years of age. All patients were in the low or
low-intermediate risk categories of the International Prognostic In-
dex. However, when we grouped patients on the basis of the NK/T cell
lymphoma prognostic index (NKPI) proposed previously for ENKTL,
which includes the presence of “B” symptoms, lesions at stages III or
IV, elevated serum LDH concentration, and lymph node involve-
ment,20 nine patients belonged to group III or IV (ie, those with two
risk factors).
Response
In the first stage, six patients were entered onto the study, and five
of these experienced CR. After this preliminary result, 30 patients were
registered. After CCRT, the overall response rate, which included 22
CRs and eight PRs, was 100% (Fig 2). After VIPD chemotherapy, 19
patients retained CRs, and five patients with PRs to CCRT achieved
CR (Fig 2). Twenty-four patients achieved CR after the completion of
VIPD (CR rate, 80.0%; 95% CI, 65.69 to 94.31).
Relapse
Four (13.33%) of 30 patients experienced disease progression
(95% CI, 1.17 to 25.49). Systemic progression was observed in one
patient (a 60-year-old woman) when new lesions were found in her
breast. After progression, she refused additional treatment, and she
died 3 months later. Local disease progression was found in two
patients: one patient (a 54-year-old man) experienced a relapse in the
left nasal cavity within his previous radiation field, and the other
patient (a 65-year-old man), who was still in PR after the completion
of treatment, experienced disease progression in the laryngopharyn-
geal area just outside the border of the radiation field. Local as well as
systemic relapse was found in one patient (a 58-year-old man). He
experienced relapse in the nasal cavity and had multiple skin lesions
(Fig 2). All three of these male patients were treated with the sol-
umedrol, methotrexate, ifosfamide, L-asparaginase, and etoposide
(SMILE) regimen.21 However, only one patient (a 54-year-old man)
remained alive after treatment at the time of this article.
Toxicity
Hematologic toxicity was minimal during CCRT; grades 1 to 2
leukopenia were observed in seven patients (23.3%, Table 2). Nonhe-
matologic toxicities were tolerable, and most toxicities were grade 1.
Although one patient had grade 3 nausea, he could continue treat-
ment without interruption, because his nausea was controlled by
supportive care. The other grade 2, nonhematologic toxicities were
managed so there was no delay or interruption of CCRT. However,
one patient (a 47-year-old man) dropped out after CCRT and with-
drew his consent for personal reasons.
Grades 3 to 4 hematologic toxicities were frequent during VIPD.
Anemia and thrombocytopenia were less severe in patients than was
leukopenia (Table 2). Eight patients experienced grade 4 leukopenia.
There were two deaths associated with complications because of infec-
tion: one patient (a 73-year-old man) died as a result of gram-positive
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Patients
No. %
Age, years
 60 26 86.7
 60 4 13.3
Sex
Male 17 56.7
Female 13 43.3
ECOG performance status
0 17 56.7
1 13 43.3
Ann Arbor stage
I 15 50.0
II 15 50.0
Serum LDH
Normal 24 80.0
Increased 6 20.0
“B” symptoms
Absent 19 63.3
Present 11 36.7
EBV titration, copies/L
 64 19 63.3
 64 11 36.7
LN involvement
Absent 19 63.3
Present 11 36.7
Platelet count
 150,000/mm3 3 10.0
 150,000/mm3 27 90.0
Absolute lymphocyte count
 1,000/mm3 7 23.3
 1,000/mm3 23 76.7
IPI
0/1 23 76.7
2 7 23.3
NK prognostic index group
I/II 21 70.0
III/IV 9 30.0
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase; EBV, Epstein-Barr virus; LN, lymph node; IPI, International
Prognostic Index; NK, natural killer.
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sepsis while neutropenic, and the other patient (a 39-year-old man)
died before the start of the third cycle of VIPD. However, this death
might be related to disease progression, because the patient was not
neutropenic and because no microbiologic evidence of infection was
found, although the final cause of his death was suspected to be septic
shock. One patient (a 60-year-old woman) withdrew her consent after
the first cycle of VIPD because of grade 3 hematologic toxicity (Fig 2).
Survival and Prognostic Factor Analysis
Three-year OS and PFS rates were 86.28% and 85.19%, respec-
tively. These survival outcomes were superior to those for our previous
patient cohort that was treated with dose-intensified CHOP followed
by radiotherapy (Fig 3).22 A platelet count less than 150,000/mm3 and
an absolute lymphocyte count less than 1,000/mm3 were significant,
poor prognostic factors for OS and PFS in univariate analysis
(P .05). When we dichotomized patients on the basis of the cutoff
value of our previous report (ie, 64 copies/L EBV DNA), elevated
titer of EBV DNA ( 64 copies/L) was also associated with worse
PFS (P  .044).23 However, other parameters, including age, Ann
Arbor stage, serum LDH, B symptoms, lymph node involvement, and
International Prognostic Index, were not prognostic for OS and PFS.
Multivariate analysis failed to show any independent prognostic factor
for PFS and OS.
DISCUSSION
This study applied frontline treatment with CCRT followed by non–
anthracycline-based chemotherapy for stages IE to IIE nasal ENKTL.
For CCRT, we performed a weekly cisplatin administration as a radio-
sensitizer to augment the efficacy of radiotherapy as well as to reduce
the amount of radiation. The CR rate after CCRT was 73.3%, which
was superior to the rates reported in previous studies of chemotherapy
followed by radiotherapy.1-3 This CR rate was comparable to those
reported in previous studies of treatment with radiotherapy alone,12,18
but our radiation doses (median, 40 Gy; range, 40 to 52.8 Gy) were
smaller than in previous studies, in which doses greater than 45 to 70
Gy were used. In this study, 19 patients received 40 Gy, nine patients
received 40 to 44 Gy, one patient received 46 Gy, and one patient
received 52.8 Gy. A previous study suggested that radiation doses of
more than 52 Gy might be required to obtain in-field control in
patients with localized ENKTL.13 Another reported that a radiation
dose of less than 45 Gy was significantly associated with local relapse.12
However, we achieved satisfactory local control with acceptable toxic-
ity by using CCRT.
VIPD chemotherapy was added to the regimen to prevent sys-
temic relapse and for consolidation. Five patients who experienced
CCRT
CR (n = 22)
VIPD
PR (n = 8)
Withdrawal (n = 2)
Male, age 47 years, 
  after CCRT
Female, age 60 years, 
  after VIPD No. 1
PD (n = 1)
Female, age 55 years, breast 
CR (n = 19)
Infection (n = 2)
Male, age 73 years, 
  after VIPD No. 1
Male, age 39 years, 
  after VIPD No. 2
PR (n = 1)
CR (n = 5)
Follow-up
Relapse (n = 1)
Male, age 54 years, 
  nasal cavity 
CR (n = 22)
Relapse (n = 1)
Male, age 58 years, 
  skin/nasal cavity
Progression (n = 1)
Male, age 65 years, 
  laryngopharynx
Fig 2. Summary of treatment outcomes
and treatment failures. CCRT, concurrent
chemoradiotherapy; CR, complete response;
VIPD, etoposide, ifosfamide, cisplatin, and
dexamethasone; PD, progressive disease;
PR, partial response.
Table 2. Toxicity Profiles
Toxicity
Adverse Event by Treatment Group and Event Grade
CCRT VIPD
1 2 3 4 1 2 3 4
Hematologic
Anemia 10 4 11 7 1
Leukopenia 2 5 5 4 6 8
Thrombocytopenia 5 7
Febrile neutropenia 15 3
Nonhematologic
Nausea 13 10 1 10 7 1
Vomiting 6 3 3 4 1
Diarrhea 2 2
Anorexia 5 1 5
Constipation 2 1 4
Stomatitis 7 4 5 1
Azotemia 3
Gastritis 1
Neuropathy 6 6 1
Abbreviations: CCRT, concurrent chemoradiotherapy; VIPD, etoposide, ifos-
famide, cisplatin, and dexamethasone.
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PRs then experienced conversion to CR after VIPD chemotherapy,
which resulted in an 80.0% CR rate (ie, 24 or 30 patients; 95% CI,
65.69 to 94.31). Furthermore, only four patients experienced dis-
ease progression or relapse during follow-up: one was, systemic,
two were local, and one was combined systemic and local relapse.
Because the one local relapse occurred outside the radiation field, and
because the other patient had simultaneous systemic relapse, the true
local relapse rate was only 3.3% (ie, one of 30 patients), and the rate of
systemic relapse was 10% (ie, three of 30 patients). A previous retro-
spective analysis of 102 patients treated with radiotherapy alone re-
ported a higher local relapse rate (47%) and systemic relapse rate
(27%).12 In a recent nationwide analysis that included 105 patients
with stages IE to IIE ENKTL, the local failure rate (29%) also was
higher than the one we observed in our patients.8 Therefore, our
treatment strategy may reduce local relapse although it uses reduced
doses of radiation. Although we observed three occurrences of sys-
temic relapse, this rate was lower than that found in previous reports.
In a comparison of these results with those of our previous cohort
Table 3. Study Comparison With Previous Major Series of Stage IE/IIE, Extranodal, NK/T-Cell Lymphomas
Study by Type
No. of
Patients Study Period
Treatment
RT Dose (Gy)
CR Rate
(%)
Survival
Failure Rate (%)
Type
No. of
Patients Median Range
OS PFS
Type
Rate
(%) Type
Rate
(%) Local System†
Retrospective
Koom et al12 102 1976-1998 RT alone 45 20-70 72 5 year 42 5 year 53 47 27
Li et al8 105 1983-2003 RT alone 31 50 40-65 83 5 year 66 5 year 61 29 81
CT  RT‡ 81 5 year 76 5 year 61
CT alone 3
Cheung et al6 79 1977-2001 RT alone 18 50 30-60 77.8 5 year 29.8 5 year 30.5 46.7 75.6
CT  RT‡ 61 65.6 5 year 40.3 5 year 35.8
Wang et al24 53 1997-2001 CT  RT§ 45 36-50 81.1 2 year 75.8 2 year 61.8 18.9 15.1
Prospective
Kim et al1 17 1995-1999 CT  RT 45 40 3 year 59 Not described 64.7 5.9
Lee et al22 17 2000-2004 CT  RT¶ 44 76 3 year 67 3 year 56 11.8 29.4
This study 30 2006-2007 CCRT  CT 40 40-52.8 80 3 year 86.3 3 year 85.2 6.7 6.7
Abbreviations: NK, natural killer; RT, radiotherapy; CR, complete response; OS, overall survival; PFS, progression-free survival; CT, chemotherapy; CCRT,
concurrent chemoradiotherapy; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisone.
Local failure included locoregional relapse after treatment or progression during treatment.
†Systemic failure included systemic relapse after treatment or progression during treatment.
‡CHOP or CHOP-like treatment mainly were used.
§Six cycles of CHOP were administered and were followed by radiotherapy.
Four cycles of CHOP, followed by radiotherapy, were administered.
¶Two cycles of dose-intensified CHOP, followed by radiotherapy, were administered; after that, four cycles of CHOP were administered.
A
0
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Fig 3. Concurrent chemoradiotherapy (CCRT) followed by etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD) produced a significantly longer (A)
progression-free survival and (B) overall survival than our previous patient cohort that was treated with dose-intensified (DI) cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) chemotherapy followed by radiotherapy (RT).
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treated with dose-intensified CHOP followed by radiotherapy,22 our
systemic relapse rate (10%; ie, three of 30 patients) was lower (29.4%;
ie, five of 17 patients). We conclude that VIPD chemotherapy as an
adjuvant to CCRT was effective for reducing relapse and for augment-
ing the response achieved by CCRT.
There were frequent grades 3 to 4, hematologic toxicities during
VIPD chemotherapy, even though we reduced the doses of ifosfamide
because of the results of our pilot study. Although two patients died
during VIPD, one death was not clearly associated with treatment
toxicity, because the patient did not have neutropenia. We believe this
death may have been related to disease progression and to ENKTL-
associated hemophagocytosis with multiorgan failure, although we do
not have enough evidence to be sure.
In this study, the 3-year OS and PFS rates were approximately
86.28% and 85.19%, respectively. Although the survival benefit
should be demonstrated in a randomized, phase III study, it is not
feasible to conduct a randomized study, because ENKTL is a rare
disease. Thus, we compared the treatment outcome of our new treat-
ment strategy with our previous cohort that was treated with dose-
intensified CHOP followed by radiotherapy, because no published
data with CCRT or intensive regimens are available to compare, and
because dose-intensified CHOP is a more aggressive treatment strat-
egy than conventional treatment.22 As a result, the survival outcome of
CCRT followed by VIPD was better than our previous cohort (Fig 3).
This treatment outcome is better than previous studies of radiother-
apy alone or of combined modalities, including chemotherapy and
radiotherapy (Table 3). A recent, international, peripheral T-cell leu-
kemia study showed that the 3-year OS of stages I to II ENKTL was less
than 50%.25 Although our follow-up time was relatively short, most
relapses were reported to occur early after treatment.25 Thus, the
survival outcomes that we observed attest to the effectiveness of CCRT
followed by VIPD chemotherapy. At present, we still did not find any
kinds of long-term toxicity among survivors, although our follow-up
time was relatively short. But our cohort should be observed addi-
tionally to monitor the development of long-term toxicity, includ-
ing secondary malignancy. In conclusion, CCRT followed by VIPD
chemotherapy can be a feasible and effective treatment strategy for
stages IE to IIE nasal ENKTL.
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